C-terminal amination of a cationic anti-inflammatory peptide improves bioavailability and inhibitory activity against LPS-induced inflammation

Lulu Zhang†, Xubiao Wei†, Rijun Zhang*, Matthew Koci2, Dayong Si1, Baseer Ahmad1, Henan Guo1 and Yanfei Hou3

1 State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China, 2 Prestage Department of Poultry Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States, 3 School of Pharmaceutical Sciences, Tsinghua University, Beijing, China

Lipopolysaccharide (LPS) has been implicated as a major cause of inflammation and an uncontrolled LPS response increases the risk of localized inflammation and sepsis. While some native peptides are helpful in the treatment of LPS-induced inflammation, the use of these peptides is limited due to their potential cytotoxicity and poor anti-inflammatory activity. Hybridization is an effective approach for overcoming this problem. In this study, a novel hybrid anti-inflammatory peptide that combines the active center of Cathelicidin 2 (CATH2) with thymopentin (TP5) was designed [CTP, CATH2 (1–13)-TP5]. CTP was found to have higher anti-inflammatory effects than its parental peptides through directly LPS neutralization. However, CTP scarcely inhibited the attachment of LPS to cell membranes or suppressed an established LPS-induced inflammation due to poor cellular uptake. The C-terminal amine modification of CTP (CTP-NH2) was then designed based on the hypothesis that C-terminal amidation can enhance the cell uptake by increasing the hydrophobicity of the peptide. Compared with CTP, CTP-NH2 showed enhanced anti-inflammatory activity and lower cytotoxicity. CTP-NH2 not only has strong LPS neutralizing activity, but also can significantly inhibit the LPS attachment and the intracellular inflammatory response. The intracellular anti-inflammatory effect of CTP-NH2 was associated with blocking of LPS binding to the Toll-like receptor 4-myeloid differentiation factor 2 complex and inhibiting the nuclear factor-kappa B pathway. In addition, the anti-inflammatory effect of CTP-NH2 was confirmed using a murine LPS-induced sepsis model. Collectively, these findings suggest that CTP-NH2 could be developed into a novel anti-inflammatory drug. This successful modification provides a design strategy to improve the cellular uptake and anti-inflammatory activity of peptide agents.

Keywords: C-terminal amination, cellular uptake, bioavailability, Toll-like receptor, lipopolysaccharide neutralization, NF-κB signaling
INTRODUCTION

Lipopolysaccharide (LPS), a major component of the cell wall of gram-negative bacteria, has been implicated as a major cause of inflammation (1, 2). An uncontrolled LPS response gives rise to excessive localized inflammation, such as liver inflammation (3), and severe systemic responses to infection, such as sepsis (4). Hence, LPS control and clearance is critical for avoiding excessive inflammation and organ damage. Traditionally, antibiotics, such as polymyxin B, are therapeutically important in the treatment of LPS-induced inflammation (5). Regrettably, the development of polymyxin B as an anti-inflammatory drug has faced several obstacles, primarily attributed to undesirable side effects, such as neuro- and nephrotoxicity, hampering their clinical development (5). Therefore, there is an urgent need to identify and develop new drugs that possess improved pharmaceutical profiles and reduced adverse effects.

In recent years, some native bioactive peptides have been suggested as a promising strategy to develop new anti-inflammatory agents (6–8). A wide variety of organisms, such as mammals, insects, fish, amphibians and plants, secrete peptides as important immunomodulators (9). Many native peptides have been reported to have certain inhibitory activities against LPS-induced inflammation, such as LL-37 (10–13), Cathelicidin 2 (CATH2) (14), and Thymopentin (TP5) (15, 16). Among them, CATH2 and TP5 have displayed enormous potential in the treatment of LPS-induced inflammation (14–16).

CATH2 is a highly cationic (11⁺) chicken heterophil-derived peptide. It has been reported to have strong anti-inflammatory effects through LPS neutralization (14) and regulating the mRNA expression of proinflammatory cytokines, including IL-1β, IL-6, and TNF-α (14). Therefore, DEXB126 can prevent or attenuate LPS-induced inflammation.

TP5, the Arg32–Tyr36 fragment derived from thymopoietin, was found to exert its anti-inflammatory effect by inhibiting the transcription factor NF-κB and p38 signaling cascades (15–19). Besides, TP5 plays an important role in T-lymphocyte maturation and differentiation, thereby regulating immunity and the inflammatory response (20, 21). Overall, TP5 is used in the treatment of inflammatory diseases, such as infectious diseases, due to its anti-inflammatory activities and low cytotoxicity.

However, the development of CATH2 has been weakened by its potential cytotoxicity (22). TP5 has minimal cytotoxicity, but its development has been weakened by its short half-life, which decreases its efficacy and bioavailability (23, 24). As a simple and effective strategy that can combine the advantages of different native peptides (25, 26), hybridization has been put forward to improve the anti-inflammatory activity and physiological stability and reduce the undesirable cytotoxic effects of these native peptides (25). As previously reported, CATH2 (1–13) (14) exhibits robust anti-inflammatory activities. Therefore, to obtain a novel peptide with increased anti-inflammatory activity but minimal cytotoxicity, we designed a hybrid peptide (CATH2-TP5, CTP) by combining the active center of CATH2 [CATH2 (1–13)] with TP5. The new designed peptide, CTP, efficiently inhibited LPS-induced inflammation. However, CTP only suppress the LPS-induced inflammatory response when it interacted with LPS but did hardly attenuate an established LPS-stimulated inflammation, which was speculated to be a result of poor cellular uptake.

To overcome the difficulty of peptide access and entry into the cell, various methods have been employed. For instance, introduction of histidine residues (27, 28) or addition of D-amino acids (29, 30) may enhance peptide transmembrane delivery. Furthermore, peptide hydrophobicity is required for enhanced cellular uptake (31, 32) and C-terminal amidation has been reported to enhance the hydrophobicity of peptides (33). Therefore, we attempted to modify CTP to obtain a C-terminal amidated derivative peptide (CTP-NH2) to improve cellular uptake, intracellular distribution and consequently anti-inflammatory activity. The hydrophobicity of the peptide was characterized by retention time. In vitro experiments were performed to evaluate the cytotoxicity, anti-inflammatory effect, and anti-inflammatory mechanism of the derivative peptide. Furthermore, its anti-inflammatory effects were assessed through an LPS-induced murine model of sepsis.

MATERIALS AND METHODS

Hybrid Peptide Design

The hybrid peptide CATH2-TP5 (CTP, RWGRFLKIRRFR RKDYV) was constructed by combining the active center of CATH2 (RWGRFLKIRRFRPKVTITIQGSARF) with TP5 (RKDYV). Primary sequence analysis of all the peptides was performed using ExPaSy Proteomics Server: http://www.expasy.org/tools/protparam.html.

Peptides Synthesis

The peptides CATH2, TP5, and CTP were synthesized in free C-terminal acid form, and CTP-NH2 was synthesized in amidated C-terminal acid form. The peptides were synthesized and purified by KangLong Biochemistry (Jiangsu, China). The purity of the peptides was determined by HPLC and mass spectrometry (MS). All the peptides had purities of 95% or greater. The peptides were dissolved in endotoxin-free water and stored at -80°C.

The Retention Time of Peptides

The retention time of peptides on a reverse-phase matrix has been reported to be related to peptide hydrophobicity (34). Thus, the relative hydrophobicity of hybrid peptides in aqueous
solution indicated that differences in hydrophobicity were reliably reflected by different HPLC retention times.

**Cell Culture**

Mouse macrophage (RAW264.7) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA) containing 10% (v/v) fetal bovine serum (FBS) (Gibco, Foster, CA, USA) and 1% (v/v) penicillin/streptomycin (HyClone), at 37°C in a moist atmosphere (5% CO₂, 95% air).

**Cell Viability Assay**

The viability of peptide-treated RAW264.7 cells was determined using a Cell Counting Kit-8 (CCK-8) Assay Kit (Dojindo) (35). RAW264.7 cells were plated in 96-well plates at a density of 3×10⁴ cells/ml in 100 µl DMEM overnight. The cell culture medium was then supplemented with fresh medium containing candidate peptides in a series of concentrations, and the plates were incubated for another 24 h or 72 h. Each well was incubated with 10 µl CCK-8 solution for 4 h in the dark. Afterwards, the absorbance at 450 nm was measured using a microplate reader. Cell viability was determined by:

\[
\text{Cell viability} \, (\%) = \left( \frac{\text{OD}_{450\,\text{sample}}}{\text{OD}_{450\,[\text{control}]} } \right) \times 100\%
\]

**Anti-Inflammatory Assay in the RAW264.7 Cell Line**

RAW264.7 cells were treated with or without 10 µg/ml peptides for 30 min before the addition of 100 ng/ml LPS (E. coli, O111: B4, Sigma-Aldrich, USA) at a final concentration of 1.0 U/ml was incubated with various concentrations of the peptides (0 to 64 µg/ml final concentration) at 37°C for 15 min. Afterwards, the mixtures were incubated with TAL assay reagent at 37°C for 6 min, and the absorbance was measured at 540 nm.

**Confocal Laser-Scanning Microscopy**

RAW264.7 cells were treated with N-terminus FITC-labeled peptides at 10 µg/ml for 24 h at 37°C in the dark. Then, the RAW264.7 cells were rinsed with PBS three times, fixed with paraformaldehyde and washed with PBS. The cell nuclei were stained with DAPI (diluted 1:500 in PBS) (Sigma, USA) for 5 min, and the cells were washed with PBS. The above cells were spread on a glass slide, fixed and observed with a Leica TCA sp5 confocal microscope (Germany).

**Flow Cytometry**

RAW264.7 cells were treated with 10 µg/ml N-terminus FITC-labeled peptides at 37°C in the dark for 24 h. Afterwards, the RAW264.7 cells were harvested and rinsed with PBS five times. The average FITC intensity in the cells was measured via flow cytometry.

**Neutralization of LPS**

The neutralization of LPS by the peptides was assessed through a quantitative Chromogenic End-point Tachypleus Amebocyte Lysate (CE TAL) assay using a QCL-1000 kit (XIAMEN BIOENDO TECHNOLOGY CO., China). LPS (E. coli, O111: B4, Sigma-Aldrich, USA) at a final concentration of 1.0 U/ml was incubated with various concentrations of the peptides (0 to 64 µg/ml final concentration) at 37°C for 15 min. Afterwards, the mixtures were incubated with TAL assay reagent at 37°C for 6 min, and the absorbance was measured at 540 nm.

**Western Blotting**

RAW264.7 cells plated at a density 1.8 × 10⁶ cells/ml were incubated with LPS (100 ng/ml) at 37°C for 1 h. After that, the cells were washed extensively with PBS before being treated with CTP-NH₂ for 3 h at 37°C, followed by lysis of the cells. Cytoplasmic and nuclear protein fractions were obtained using NR-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific Inc., New Zealand). The protein concentrations were assessed with a CA kit (KeyGEN Biotech. Nanjing, China) according to the manufacturer’s instructions. Afterwards, total protein (40 µg protein/lane) was separated on 10% SDS-PAGE gels and then transferred to PVDF membranes (Bio-Rad). Next, the membranes were blocked with 5% non-fat dried-milk containing 0.05% TBST and then immunoblotted with specific primary antibodies against IKK-β, p-IKK-β, IκB-α, p-IκB-α, NF-κB (p65), p-NF-κB (p-p65), and β-actin (Santa Cruz, CA, USA). After being washed with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (HuaAn, Hangzhou, China). A ChemiDoc MP Imaging System (Bio–Rad, Hercules, CA, USA) was used to quantify the density of the specific proteins.

**Molecular Dynamics Simulation**

The initial 3D structure of the peptide was generated through Chimera software. To assess the binding affinity of with the TLR4/MD-2 complex, the relevant crystallographic structure of the Toll-like receptor 4/myeloid differentiation factor 2 (TLR4/MD-2) complex was retrieved from PDB (PDB code: 2Z64). The
missing hydrogen atoms were added under pH 7.0 conditions by Maestro (36). The protein-protein docking server RosettaDock (version 3.5) was used to predict and assess interactions between the peptides and the binding target TLR4/MD-2 complex. To filter the best docking conformers, we selected conformations with the lowest binding energy and a greater number of hydrogen bonds.

The best binding poses of the peptide with TLR4/MD-2 was subjected to Molecular Dynamics (MD) simulation under AMBER14 (37, 38). The protein systems were treated with GAFF and FF14SB and were solvated under the periodic boundary conditions in a cubic box with the TIP3P water model (39). Na+ and Cl- atoms were added to mimic physiological conditions and neutralize each system before the production. The system was first minimized with 5,000 steps by the conjugate gradient algorithm, followed by heating gradually in 100 ps. Subsequently, the volume of the system was adjusted at constant pressure (NPT: the number of particles, pressure of the system and temperature of the system remained constant) (40). After that, the equilibrated structures were simulated under a constant number, volume, and temperature (NVT) for 60 ns.

Based on the 300 snapshots extracted from the last 40 ns of the equilibrated MD simulation, the binding energy was calculated based on the molecular mechanics Poisson-Boltzmann accessible surface area (MM-PBSA) method (41). The Particle-mesh Ewald (PME) method was used to calculated the long-range electrostatic interactions of the system (42).

**Surface Plasmon Resonance (SPR)**

SPR assays were performed using a Biacore X100 instrument (GE Healthcare, Pittsburgh, PA, USA). PBS containing 0.05% Tween 20 was used as the running buffer. The running buffer was continuously passed into the reaction chamber at 30 µl/min. Immobilization of CTP-NH₂ on the chip surface was performed according to the conjugate coupling protocol. To obtain the sensorgrams of the interactions between the peptides and TLR4/MD-2 complex, a range of peptide concentrations (0, 1.25, 2.5, 5, and 10 mM) were analyzed. Running buffer was injected into the empty channel as a reference. To regenerate the chip surface at the end of each experiment, 10 mM Gly-HCl buffer (pH 2.5) was injected. ProteOn manager software (version 2.0) was used to analyze the experimental data. The binding curves were processed for the start injection alignment and baseline. A reference-subtracted sensorgram was then fitted to the curves describing a homogeneous 1:1 model. Data from the protein surfaces were grouped together to fit the association kinetic rate constant (Kₐ) and the dissociation rate constant (K_d). The equilibrium dissociation constant (KD) for the peptide-TLR4/MD-2 interaction was calculated as follows:

\[ K_D = K_d/K_a \]

**Animal Model**

Male C57/BL6 mice (6–8 weeks of age) were purchased from Charles River (Beijing, China). The mice were maintained in a specific-pathogen-free (SPF) environment at 22 ± 1°C with relative 55 ± 10% humidity during the experiments. The assays were performed in conformity with the laws and regulations for live animal treatments at China Agricultural University.

The mice were randomly distributed into three groups (n = 12 each): control, LPS (E. coli, O111:B4, Sigma-Aldrich, USA) treatment, and CTP-NH₂ pretreatment followed by LPS treatment (CTP-NH₂ + LPS). For the first 7 days, CTP-NH₂ (10 mg/kg mouse weight) was injected intraperitoneally once daily. Meanwhile, an equal volume of sterile saline was injected into mice in the control and LPS-treated groups. On day 7, LPS (10 mg/kg mouse weight) was injected intraperitoneally injected with an equal volume of saline. Sixteen hours after the LPS injection, the mice were euthanized by cervical dislocation, and samples of the intestine were collected for analysis.

**Histopathology and Immunohistochemistry**

The mouse liver tissues were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 5-µm-thick sections using an RM2235 microtome (Leica, Germany). The sections were stained with hematoxylin-eosin (H&E), and a DM3000 microscope was used to acquire images. LPS-induced liver injury was evaluated according to the following four categories: alveolar congestion, hemorrhage, neutrophil infiltration into the airspace or vessel wall, and thickness of alveolar wall/hyaline membrane formation. The liver injury score was graded on a 0- to 4-point scale: 0, no injury; 1, up to 25% injury in the field; 2, up to 50% injury in the field; 3, up to 75% injury in the field; 4, diffuse injury (43).

For immunohistochemical analysis, the sections were blocked with PBS containing 1% w/v BSA for 1 h at room temperature. Afterwards, the sections were incubated with anti-CD177 antibody (1:100; Santa, USA). Samples were washed with PBS followed by incubation with horse-radish peroxidase (HRP)-conjugated rabbit anti-goat IgG (1:100; JIR, USA) at 4°C for 1 h. Subsequently, slides were stained with 3,3′-diaminobenzidine (DAB; DAKO, USA) and then counterstained with Harris hematoxylin. Finally, the samples were dehydrated in an alcohol gradient (70-100%) and cleared in xylene. All slides were mounted in neutral balsam.

**ELISA**

The levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β in cell culture supernatants and the levels of TNF-α, IL-6, and IL-1β in the serum of mice were detected using commercial ELISA kits (eBioscience, San Diego, USA) according to the manufacturer’s instructions. The levels of serum alanine amino transferase (ALT) and aspartate amino transferase (AST) were detected using commercial reagent kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The activity of myeloperoxidase (MPO) in the liver of mice was detected using an ELISA kit (Boster, Wuhan, China) according to the manufacturer’s instructions.

**Statistics**

All the data are expressed as the mean values ± standard deviation of at least three independent experiments. Statistical
comparisons were carried out with Student’s t test using GraphPad Prism v6 software (La Jolla, California). Significance was claimed at p values ≤ 0.05; NS: p > 0.05, *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, and ****: p ≤ 0.0001.

RESULTS

Peptide Design and Characterization

As shown in Table 1, the hybrid peptide CTP was designed by combining the core functional region of CATH2 with TP5. MS was used to verify the molecular weight of the peptides. The measured molecular weights of the peptides were in agreement with the theoretical values, which suggested that the peptides were successfully synthesized.

Cytotoxicity on RAW264.7 Macrophage Cells

The cytotoxic activity of CTP and its parental peptides towards RAW264.7 macrophages was determined with CCK-8 assays (Figure 1). RAW264.7 macrophages were treated with the peptides at a series of concentrations ranging from 0 to 80 μg/ml. CTP exhibited lower cytotoxicity than the parental peptide (CATH2) but higher cytotoxicity than TP5. After incubation with 10 μg/ml peptides for 24 h (Figure 1A) and 72 h (Figure 1B), the viability of peptide-treated RAW264.7 cells was greater than 80%. These data indicate that at 10 μg/ml all the peptides were minimally cytotoxic to RAW264.7 cells and thus suitable for further anti-inflammatory experiments.

TABLE 1 | Key physicochemical parameters of parental and hybrid peptides.

| Peptides | Sequence | H* | Net charge |
|----------|----------|----|------------|
| CATH2    | RWGRRLRIRFPKVTITIQGSAEF | -0.638 | +9 |
| TP5      | RKDVT    | -1.680 | +1 |
| CTP      | RWGRRLRIRFPKVTITIQGSAEF | -1.483 | +8 |

*The mean hydrophobicity [H] is the total hydrophobicity (sum of all residue hydrophobicity indices) divided by the number of residues.

Anti-Inflammatory Effect of CTP in LPS-Stimulated RAW264.7 Cells

To evaluate the anti-inflammatory effect of CTP and its parental peptides, CATH2 and TP5, RAW264.7 cells were used as a model. The results showed that LPS caused significant elevation of the pro-inflammatory cytokines TNF-α (Figure 2A), IL-6 (Figure 2B), and IL-1β (Figure 2C) compared with untreated cells. As shown in Figures 2A–C, all the peptides attenuated the TNF-α, IL-1β, and IL-6 secretion levels. Furthermore, compared with its parental peptides, CTP exerted enhanced inhibitory activity against LPS-induced inflammation.

CPT Exerts Its Anti-Inflammatory Effect Through LPS Neutralization Activity

To identify the anti-inflammatory mechanisms of CTP, a time of addition experiment for CTP against LPS-induced inflammation was performed. LPS or RAW 264.7 cells were incubated with CTP at 10 μg/ml for different periods of time, and the anti-inflammatory effects were measured by ELISA. After incubation with LPS, CTP exhibited potent inhibition of pro-inflammatory cytokine release, including TNF-α (Figure 3A) and IL-6 (Figure 3B), suggesting that CTP might exert its anti-inflammatory activity through interacting with LPS. To verify how CTP works on LPS, an additional test was performed in vitro. The results showed that CTP inhibited activation of LPS in a dose-dependent manner (Figure 3C). The 50% binding rate value of CTP was approximately 45.32 ± 5.19 μg/ml. In contrast, CTP scarcely reduced the elevation in the pro-inflammatory cytokines TNF-α (Figure 3A) and IL-6 (Figure 3B) when used to pretreat cells or added to cells after LPS induction. These results suggested that CTP only exerted anti-inflammatory activity when directly interacting with LPS but did not inhibit LPS attachment or affect intracellular anti-inflammatory activity.
Considering the significant difference between the extracellular and intracellular anti-inflammatory activities of CTP, we speculated that CTP may have low cellular uptake in RAW264.7 cells and/or unfavorable intracellular localization. RAW264.7 cells were incubated with FITC-labeled CTP at 10 μg/ml and then examined by confocal microscopy. As shown in Figure 3D, FITC-labeled CTP rarely entered RAW264.7 cells, which explained its low intracellular anti-inflammatory activity.

Design of an Amidation-Modified Peptide Based on the Molecular Template of CTP
CTP was designed and modified to produce a C-terminal amidated derivative peptide, CTP-NH₂. The structure and molecular weight of CTP-NH₂ were verified by MS. The HPLC retention time was used to reliably reflect the hydrophobicity of CTP and CTP-NH₂ in aqueous solution (44). The retention time for CTP and CTP-NH₂ was 10.94 min and 11.96 min, respectively, indicating that CTP-NH₂ is more hydrophobic than CTP (Table 2).

Anti-Inflammatory Activities and Cellular Uptake of the CTP Derivative Peptide (CTP-NH₂)
The cytotoxicity of the CTP derivative peptide CTP-NH₂ in RAW264.7 cells was evaluated with CCK-8 assays (Figures 4A, B). As the results showed, CTP-NH₂ exhibited less cytotoxicity than CTP, indicating that CTP-NH₂ was suitable for subsequent experiments. The CTP-NH₂ modes of action were determined by time of addition experiments as previously described. After incubation with LPS, CTP-NH₂ exhibited more potency than CTP in inhibiting TNF-α (Figure 5A) and IL-6 (Figure 5B) secretion. In addition, the LPS neutralization activity of CTP-NH₂ was stronger than that of CTP (Figure 5C). These results indicate that CTP-NH₂ has greater inhibitory activity against LPS-induced inflammation through neutralization of LPS. Interestingly, CTP-NH₂ also reduced the concentration of TNF-α (Figure 5A) and IL-6 (Figure 5B) when used to pretreat cells or added to cells after LPS induction, whereas CTP barely exerted such effects.
To determine whether internalization of the CTP derivative peptide CTP-NH₂ was promoted by amination of the C-terminus, CTP and CTP-NH₂ were labeled with FITC and incubated with RAW264.7 cells for 24 h. Afterwards, confocal microscopy and flow cytometry were used to measure the cellular uptake and localization of the peptides. The results showed that CTP-NH₂ promoted significant cellular uptake and a dispersed distribution compared with CTP (Figures 5D, E).

To determine whether internalization of the CTP derivative peptide CTP-NH₂ was promoted by amination of the C-terminus, CTP and CTP-NH₂ were labeled with FITC and incubated with RAW264.7 cells for 24 h. Afterwards, confocal microscopy and flow cytometry were used to measure the cellular uptake and localization of the peptides. The results showed that CTP-NH₂ promoted significant cellular uptake and a dispersed distribution compared with CTP (Figures 5D, E).

**TABLE 2 |** Key parameters of CATH2-TP5 (CTP) and its C-terminal amidated derivative peptide CTP-NH₂.

| Peptides       | Sequence         | Theoretical Mw | Measured Mw | Retention time (min) |
|----------------|------------------|----------------|-------------|----------------------|
| CTP            | RWGRFLRKRFFRKDVDT | 2445.91        | 2446.25     | 10.94                |
| CTP-NH₂        | RWGRFLRKRFFRKDVDT-NH₂ | 2445.91        | 2445.91     | 11.96                |
**CTP-NH$_2$ Exerted Intracellular Anti-Inflammatory Activity by Binding TLR4/MD-2 and Inhibiting the NF-κB Signaling Pathway**

To investigate the intracellular anti-inflammatory mechanism of CTP-NH$_2$, binding of CTP-NH$_2$ to TLR4/MD-2 was examined via an SPR assay. A series of concentrations ranging from 0 to 10 μM were passed over immobilized TLR4/MD-2. The results showed that the peptides binding to the chip-bound protein exhibited a dose-dependent increase (Figures 6A, B). The calculated $K_a$ and $K_d$ values for CTP-NH$_2$ and TLR4/MD-2 binding were $1.65 \times 10^7$ s$^{-1}$ and $1.56 \times 10^4$ M$^{-1}$s$^{-1}$, and the $K_d$ value was $9.47 \times 10^{-1}$ μM (Figure 6B). Besides, the calculated $K_a$ and $K_d$ values for CTP and TLR4/MD-2 binding were $1.34 \times 10^7$ s$^{-1}$ and $1.87 \times 10^4$ M$^{-1}$s$^{-1}$, and the $K_d$ value was $1.40$ μM (Figure 6A). These results confirmed that the binding affinity of CTP-NH$_2$ for the TLR4/MD-2 receptor was higher than that of CTP for TLR4/MD-2.

Afterwards, to further predict the binding effect of CTP-NH$_2$ to the TLR4/MD-2 complex, an MD simulation was performed. A total of 300 snapshots for the peptide-TLR4/MD-2 complex were observed from the last stable 40 ns of the MD simulation. The binding free energy was used to reflect the binding affinity of peptide. As shown in Table 3, the binding energy of CTP-NH$_2$ was $-1,181.25$ kJ/mol, which was higher than the binding energy of CTP. In addition, the interface of TLR4/MD-2 that is bound to CTP-NH$_2$ exhibited more hydrogen bonds and salt bridges, and a larger interaction surface area, than those of the TLR4/MD-2-CTP pairs. This is consistent with the SPR results and suggests that CTP-NH$_2$ exerts its intracellular anti-inflammatory activity by blocking LPS binding to the TLR4/MD-2 complex.

Next, the NF-κB signaling pathway was investigated to determine the intracellular anti-inflammatory mechanism of CTP-NH$_2$. LPS significantly increased the phosphorylation of IKK-β, IκB-α, and NF-κB, while cells that were treated with CTP-NH$_2$ exhibited dampened levels of IKK-β, IκB-α, and NF-κB (Figure 7). These results suggest that the intracellular anti-inflammatory effect of CTP-NH$_2$ on the NF-κB signaling pathway plays a crucial role in the process by which CTP-NH$_2$ modulates LPS-induced inflammation.

**The Protective Effects of CTP-NH$_2$ Against LPS-Induced Sepsis**

To characterize the inhibitory effect of CTP-NH$_2$ against LPS-induced sepsis, the concentrations of the inflammatory markers TNF-α, IL-6, and IL-1β in mouse serum were quantified via ELISA. Compared with the control group, LPS challenge led to significant increased levels of TNF-α (Figure 8A), IL-6 (Figure 8B), and IL-1β (Figure 8C) in the serum of mice, whereas the CTP-NH$_2$-pretreated group showed significantly decreased levels of TNF-α, IL-6, and IL-1β compared with those in the LPS-treated group.

LPS clearly caused an increase in ALT and AST, markers of liver function, whereas CTP-NH$_2$ significantly attenuated these effects (Figures 8D, E). Furthermore, compared with the control group, LPS caused considerable tissue injury, with disturbed hepatic architecture, extensive hemorrhage, hepatocyte necrosis and inflammatory cell infiltration (Figure 8G). By contrast, the severity of liver injury was attenuated by CTP-NH$_2$ pretreatment (Figure 8F). These protective effects were confirmed by liver injury score analysis (Figure 8F).

Moreover, immunohistochemistry results showed that LPS triggered increased infiltration of CD177$^+$ neutrophils into the liver lesion area compared with the control (Figure 8H).
FIGURE 5 | Anti-inflammatory activity and intracellular distribution of CTP-NH₂. Anti-inflammatory activity assay of CTP-NH₂ in the time addition experiment. The TNF-α (A) and IL-6 (B) concentrations show the anti-inflammatory effect of CTP-NH₂ in each treatment mode. (C) In vitro LPS neutralization by CTP-NH₂. The lipopolysaccharide (LPS) neutralization activity of CTP-NH₂ was assessed in vitro using a chromogenic TAL assay. (D) Confocal microscopic examination of cellular localization of CTP and CTP-NH₂. FITC-labeled CTP or CTP-NH₂ was used to treat RAW264.7 cells for 24 h, and cellular localization was assessed with confocal microscopy. The same image of CTP cellular localization is used in both Figure 5D and Figure 3D. Scale bars: 10 μm. (E) Flow cytometry measurement of the cellular uptake of CTP and CTP-NH₂. The peptides were labeled with FITC and incubated with RAW264.7 macrophages for 24 h, and the average FITC intensity in each cell was determined by flow cytometry. Data are given as the mean value ± SD from at least three biological replicates. NS: p > 0.05, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
However, the infiltration of neutrophils was significantly lower in the CTP-NH₂-pretreated group than in the LPS-treated group. As an index of neutrophil infiltration and inflammation (46), the activity of MPO in the mouse liver was evaluated by ELISA. Consistent with the immunohistochemistry results, the MPO activity was markedly increased in LPS-treated mice, but pretreatment with CTP-NH₂ significantly reduced this effect (Figure 8I).

DISCUSSION

In the recent years, many anti-inflammatory peptides have been discovered or designed, and some have exerted potential LPS...
neutralization activity (7, 47, 48). However, their development has been weakened by several concerns, including potential cytotoxicity (22) and weak physiological stability and poor anti-inflammatory activity (49). To obtain a novel anti-inflammatory peptide with increased activity but minimal cytotoxicity, hybridization has been proposed (50, 51). Our group has completed several studies of hybrid anti-inflammatory peptide designs that can improve the anti-inflammatory activity and reduce the undesirable cytotoxic effects of native peptides (52, 53). Anti-inflammatory experiments showed that the new designed peptides can inhibit LPS-induced inflammation by neutralizing LPS, binding to the TLR4/MD-2 complex or inhibiting the NF-κB signaling pathway (52, 53).

In this study, we designed a hybrid peptide by combining the active center of CATH2 (1–13) (14) with TP5. The anti-inflammatory activities of the hybrid peptide and its parental peptides were verified by ELISAs in RAW264.7 cells. CTP, the new designed peptide, markedly reduced the levels of TNF-α, IL-6, and IL-1β compared with its parental peptides, CATH2 and TP5. The cytotoxicity of CTP was further tested, and the results showed that CTP had lower cytotoxicity than its parental peptide (CATH2). In addition, CTP is minimally toxic at a concentration of 10 μg/ml. Unfortunately, CTP scarcely exerted inhibition of TNF-α and IL-6 secretion when preincubated with cells before LPS induction or added to cells after LPS induction. Furthermore, CTP only exhibited inhibition when added to the cells being incubated with LPS. Confocal microscopy and flow cytometry analyses showed that CTP exhibited extremely poor cellular uptake because no visible FITC-labeled CTP was detected in the incubated cells.

To overcome the difficulty of peptide access and entry into the cell, various methods have been employed. For instance, introduction of histidine residues (27, 28) or addition of D-amino acids (29, 30) may enhance peptide transmembrane delivery. Furthermore, peptide hydrophobicity is required for enhanced cellular uptake (31, 32) and C-terminal amidation has been reported to enhance the hydrophobicity of peptides (33).

### TABLE 4 | Distance and salt-bridges of binding residues between the peptide and MD-2.

| Peptide | Interaction Pair | MD-2...CTP-NH$_2$ | Distance (Å) | Number of salt-bridges |
|---------|-----------------|-------------------|--------------|------------------------|
| CTP     | F126...K8       | 2.89              | 0            |
|         | E122...R11      | 2.73              | 1            |
|         | Y99...R14       | 3.12              | 0            |
|         | Y99...T18       | 3.09              | 0            |
|         | P88...R13       | 3.25              | 0            |
|         | L78...R13       | 3.11              | 0            |
|         | E92...R14       | 2.79              | 0            |
|         | E92...R10       | 2.67              | 2            |
| CTP-NH$_2$ | F126...K8   | 2.89              | 0            |
|         | E122...R11      | 2.53              | 2            |
|         | Y99...R14       | 3.12              | 0            |
|         | Y99...T18       | 3.09              | 0            |
|         | P88...R13       | 3.25              | 0            |
|         | L78...R13       | 3.11              | 0            |
|         | E92...R14       | 2.49              | 2            |
|         | E92...R10       | 2.27              | 3            |
|         | S48...T18       | 2.05              | 0            |
|         | F151...R14      | 3.31              | 0            |
|         | F151...R10      | 2.74              | 0            |

### FIGURE 7 | Effect of CTP on the NF-κB signaling pathways. Phosphorylated and total protein levels of IKK-β, IκB-α, NF-κB, and β-actin from serum were measured by western blot analysis. *p ≤ 0.05, and **p ≤ 0.01.
The protective effects of CTP-NH2 against LPS-induced sepsis in mice. (10 mg/kg) were injected into the mice once daily for 6 days, whereas the control and LPS-treated groups were injected with an equal volume of sterile saline. On day 6, mice in the LPS and peptide-pretreatment groups were injected with LPS (10 mg/kg) 1 h after the peptide or saline treatment. The control group was injected with an equal volume of saline. ELISAs were performed to detect TNF-α, IL-6, and IL-1β in serum. The expression of alanine amino transferase (ALT) and aspartate transaminase (AST) in serum. The effect of CTP-NH2 on liver injury scores. Representative H&E-stained sections from the (a) control, (b) LPS, and (c) CTP-NH2 + LPS groups. Bar, 50 μm. Formalin-fixed, paraffin-embedded, 5-mm cross-sections were stained with a primary Ab against CD177+. (a) control, (b) LPS, and (c) CTP-NH2 + LPS groups. The enzymatic activity of MPO was measured. Data are given as the mean value ± SD from at least three biological replicates. ***p ≤ 0.001.
These studies suggested that C-terminal amidation can be used to enhance cellular uptake and anti-inflammatory activity (54, 55).

In our study, CTP was designed and modified to produce a C-terminal amidated derivative peptide. The HPLC retention time showed that the derivative peptide (CTP-NH₂) exhibited stronger hydrophobicity than CTP. In addition, the derivative peptide CTP-NH₂ showed improved anti-inflammatory activities and decreased cytotoxicity. TNF-α and IL-6 secretion analysis showed that CTP-NH₂ exhibited greater inhibitory activity against LPS-induced inflammation when incubated with LPS in cell culture medium compared with CTP, which may be due to the stronger LPS neutralization activity of CTP-NH₂. Furthermore, it is worth noting that CTP-NH₂ also reduced the concentration of TNF-α and IL-6 when used to pretreat cells or added to cells after LPS induction, whereas CTP barely exerted such effects. Flow cytometry and confocal microscopy results showed that CTP-NH₂ exhibited considerable cellular uptake and a dispersed distribution, which may explain its anti-inflammatory activity. Therefore, these results indicate that the C-terminal amidation of CTP molecules can enhance hydrophobicity and thus overcome barriers in cellular uptake and improve anti-inflammatory activity.

To identify the mechanisms of the observed anti-inflammatory effects when cells were pretreated with the peptide or the peptide was added to cells after LPS induction, a comprehensive and detailed analysis was performed. Toll-like receptor (TLR) is endowed with the capacity to sense conserved molecular patterns on microbial pathogens and mount immune responses in host defense (56, 57). TLR4 is primarily activated by LPS recognition through an accessory protein-MD-2 (58). Hence, blocking TLR4/MD-2 is a potential mechanism for attenuation of the LPS-induced inflammatory response (59–61). To investigate the ability of CTP-NH₂ to bind to the TLR4/MD-2 complex, SPR binding assays were performed. The SPR results confirmed that CTP-NH₂ could effectively bind to TLR4/MD-2. Consistently, MD simulation showed that CTP-NH₂ could bind to the hydrophobic pocket of MD-2, which partially overlaps with the LPS binding site on MD-2 (45). Thus,
the results suggest that CTP-NH₂ confers its anti-inflammatory activity through blocking LPS binding to the TLR4/MD-2 complex. Furthermore, LPS is a strong activator of the NF-κB signaling pathway though its interaction with TLR4 (62). Thus, NF-κB plays a crucial role in host defenses through regulation of inflammatory gene expression (63). In the present study, the expression of the major proteins involved in the NF-κB pathway were detected by western blotting to elucidate the anti-inflammatory mechanism of CTP-NH₂. The results showed that CTP-NH₂ effectively inhibited activation of the NF-κB pathway by decreasing the phosphorylation of IKK-β, IκB-α, and NF-κB.

The in vivo anti-inflammatory activities of CTP-NH₂ were also evaluated in an LPS-induced murine model of sepsis. LPS, a major endotoxin, has been considered a major cause of sepsis (3). In addition, 20 mg/kg LPS has been reported to induce sepsis in vivo, which can cause excessive inflammation and organ failure, such as in liver tissue (64). Consistent with previous studies, the present study showed that the levels of TNF-α, IL-6, and IL-1β were markedly increased in LPS-treated mice, while pretreatment with CTP-NH₂ efficiently reduced this effect. Liver injury is considered one of the most serious health problems in the world, can result from diverse etiologies and is associated with high mortality (65). In this study, LPS induced liver injury, with obvious changes in biochemical and histopathological parameters. As biochemical markers of liver injury, AST and ALT are used to reflect liver injury during clinical trials. The present study showed that AST and ALT were markedly increased by LPS. However, CTP-NH₂ effectively decreased the AST and ALT levels. In addition, histological analysis showed that CTP-NH₂ repaired hemorrhage and cellular necrosis in the liver. The infiltration of activated neutrophils, one of the most representative histological features observed in liver inflammation (66), was significantly increased in LPS-treated mice. However, pretreatment with CTP-NH₂ prevented infiltration of activated neutrophils in the liver. Consistent with this, liver MPO activity, an index of neutrophil infiltration and inflammation, was significantly increased in LPS-treated mice, but pretreatment with CTP-NH₂ significantly reduced this effect. Collectively, these results indicate that CTP-NH₂ can efficiently prevent LPS-induced sepsis in mice.

CONCLUSION
The successful design and modification of CTP may provide an avenue to modify previously discovered peptides to improve their anti-inflammatory properties or design novel active peptide agents with excellent cellular uptake and anti-inflammatory activities (Figure 9). In addition, our study revealed that the anti-inflammatory effects of CTP-NH₂ associated with LPS neutralization, binding activity on the TLR4/MD-2 complex, and inhibition of the NF-κB signaling pathway.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The animal study was reviewed and approved by Institutional Animal Care and Use Committee of China Agricultural University.

AUTHOR CONTRIBUTIONS
LZ, XW, RZ, MK, and DS conceived the project and designed the experiments. LZ, XW, BA, and HG conducted experiments. LZ and MK wrote the manuscript and analyzed data. All authors read and commented on the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by the National Key Research and Development Program of China (Project No. 2018YFD0500600), the National Natural Science Foundation of China (NSFC, 31572442), and the National Natural Science Foundation of China (NSFC, 31272476).

REFERENCES
1. Gibson PR. Increased gut permeability in Crohn’s disease: is TNF the link? Gut (2004) 53(12):1724–5. doi: 10.1136/gut.2004.047092
2. Matriclon J. Immunopathogenesis of inflammatory bowel disease. M S-Med Sci (2010) 26(4):405–10. doi: 10.1051/medics/2010264405
3. Ge XT, Feng ZG, Xu TT, Wu BB, Chen HJ, Xu FL, et al. A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo. Drug Des Dev Ther (2016) 10:1947–59. doi: 10.2147/DDDT.S101499
4. Ning CQ, Gao XG, Wang CY, Huo XK, Liu ZH, Sun HJ, et al. Protective effects of ginsenoside Rg1 against lipopolysaccharide/D-galactosamine-induced acute liver injury in mice through inhibiting toll-like receptor 4 signaling pathway. Int Immunopharmacol (2018) 61:266–76. doi: 10.1016/j.intimp.2018.06.008
5. Poiriel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev (2017) 30(2):537–96. doi: 10.1128/Cmr.00064-16
6. Heinbockel L, Weindl G, Martinez-de-Tejada G, Correa W, Sanchez-Gomez S, Barcena-Varela S, et al. Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep 19-2.5. Front Immunol (2018) 9:1704. doi: 10.3389/fimmu.2018.01704
7. Wu BC, Lee AHY, Hancock REW. Mechanisms of the Innate Defense Regulator Peptide-1002 Anti-Inflammatory Activity in a Sterile Inflammation Mouse Model. J Immunol (2017) 199(10):3592–603. doi: 10.4049/jimmunol.1700985
8. Zong X, Hu WY, Song DG, Li Z, Du HH, Lu ZQ, et al. Porcine lactoferrin-derived peptide LFP-20 protects intestinal barrier by maintaining tight junction complex and modulating inflammatory response. Biochem Pharmacol (2016) 104:74–82. doi: 10.1016/j.bcp.2016.01.009

Zhang et al. Peptide Improves Bioavailability and Anti-Inflammatory Activity

Frontiers in Immunology | www.frontiersin.org 14 February 2021 | Volume 11 | Article 618312
9. Diamond G, Beckloff N, Weinberg A, Kisch KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des (2009) 15(21):2377–92. doi:10.2174/1381612097898682332.

10. Akiyama T, Niyonsaba F, Katsurayamano C, Nguyen TT, Usio H, Fujimura T, et al. The Human Cathelicidin LL-37 Host Defense Peptide Upregulates Tight Junction-Related Proteins and Increases Human Epidermal Keratinocyte Barrier Function. *J Innate Immun* (2014) 6(6):739–53. doi: 10.1159/000362789.

11. Yu J, Mookherjee N, Wei K, Bowdish DME, Pistolic J, Li YX, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1 beta, augments immune responses by multiple pathways. *J Immunol* (2007) 179 (11):2864–91. doi: 10.4049/jimmunol.179.11.7684.

12. Barlow PG, Li YX, Wilkinson TS, Bowdish DME, Lau YE, Cosseau C, et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. *J Leukocyte Biol* (2006) 80(3):509–20. doi: 10.1189/jlb.0505560.

13. Jonsson D, Nilsson BO. The antimicrobial peptide LL-37 is anti-inflammatory and proapoptotic in human periodontal ligament cells. *J Periodontal Res* (2012) 47(3):330–5. doi: 10.1111/j.1600-0765.2011.01436.x.

14. van Dijk A, van Eldik M, Veldhuizen EJA, Tjeerdsma-van Bokhoven HLM, de Korte MR, Bikker FJ, et al. Immunomodulatory and Anti-Inflammatory Activities of Chicken Cathelicidin-2 Derived Peptides. *PloS One* (2016) 11 (2). doi: 10.1371/journal.pone.0147919.

15. Goldstein G, Sched MP, Bosse EA, Schlesinger DH, vanwauwe J. Synthetic Pentapeptide with Biological-Activity Characteristic of the Thymic Hormone Thymopoietin. *Science* (1979) 204(4399):1309–10. doi: 10.1126/science.451537.

16. Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS. Thymopentin (1996) 4(4):225.

17. Jonsson D, Nilsson BO. The antimicrobial peptide LL-37 is anti-inflammatory and proapoptotic in human periodontal ligament cells. *J Periodontal Res* (2012) 47(3):330–5. doi: 10.1111/j.1600-0765.2011.01436.x.

18. Mendling W, Koldovsky U. Investigations by cell-mediated immunologic tests for enhanced apoptotic clearance of HL-60 cells in the presence of the thymic hormone thymopoietin. *Immunol Res* (2007) 39(1):7684. doi: 10.1007/s11010-009-0172-8.

19. Kim S, Kim SS, Lee BJ. Correlation between the activities of alpha-helical antimicrobial peptides and hydrophobicity and hydrophilicity of the amphiphilic regions as R P H LPC retention times. *Peptides* (2005) 26(11):2050–60. doi: 10.1016/j.peptides.2005.04.007.

20. Liu ZH, Zhang Jj, Huang Xi, Huang LN, Li ST, Wang ZG. Magnesium sulfate inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated RAW264.7 macrophages in vitro. *J Surg Res* (2013) 179(1):E189–95. doi: 10.1016/j.jss.2012.02.012.

21. Sastry GM, Adzhigirey M, Day T, Annahimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aid Mol Des* (2013) 27(3):221–34. doi: 10.1007/s10815-012-9382-7.

22. Wang J, Li Y, Zhang J, Feng C, Lee MC, Xiong GM, Zhang W, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. *J Comput Chem* (2003) 24(16):1999–2012. doi: 10.1002/jcc.10349.

23. Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and application of a flexible empirical valence bond method. *J Comput Phys* (1984) 57:2182–90.

24. Masova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. *Perspect Drug Discovery* (2000) 18:113–35. doi: 10.1023/A:1008763014270.

25. Darden T, York D, Pedersen L. Particle Mesh Ewald - an N.Log(N) Method for Ewald Sums in Large Systems. *J Chem Phys* (2000) 113:2207. doi: 10.1021/acs.jcim.7b00717.

26. Parrinello MR A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J Chem Phys* (1981) 15(1):244. doi: 10.1021/jp00530ae.

27. Zhu X, Dong N, Wang ZY, Ma Z, Zhang LC, Ma QQ, et al. Design of imperfectly amphipathic alpha-helical antimicrobial peptides with enhanced cell selectivity. *Acta Biomater* (2014) 10(1):244–57. doi: 10.1016/j.actbio.2013.08.043.

28. Garate JA, Oostenbrink C. Lupid a from lipopolysaccharide recognition: Structure, dynamics and cooperativity by molecular dynamics simulations. *Proteins* (2013) 81(4):658–74. doi: 10.1002/prot.24223.

29. Zhang Y, Zhu JL, Guo L, Zou Y, Wang F, Shao H, et al. Cholecytokinin protects mouse liver against ischemia and reperfusion injury. *Int J Mol Sci* (2017) 18(1):286–8. doi: 10.3390/ijms18010133.

30. Xishu W, Harada Y, Fukuda K, Fukushima A. Inhibition of the Antimicrobial Peptide LL37 of Lipopolysaccharide-Induced Innate Immune Responses in Human Corneal Fibroblasts. *Invest Ophth Vis Sci* (2016) 57(1):30–9. doi: 10.1167/iovs.15-17652.
48. Romani L, Oikonomou V, Moretti S, Iannitti RG, D’Adamo MC, Villella VR, et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. *Nat Med* (2017) 23(9):590–600. doi: 10.1038/nm.4305

49. DeGraw JJ, Almquist RG, Hibbert CK, Colwell WT, Crase J, Hayano T, et al. Stabilized analogs of thymopentin. 1. 4,5-ketomethylene pseudopeptides. *J Med Chem* (1997) 40(15):2386–97. doi: 10.1021/jm950803a

50. Liu YF, Xia X, Xu L, Wang YZ. Design of hybrid beta-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity. *Biomaterials* (2013) 34(1):237–50. doi: 10.1016/j.biomaterials.2012.09.032

51. Ma Z, Wei DD, Yan P, Zhu X, Shan AS, Bi ZP. Characterization of cell selectivity, physiological stability and endotoxin neutralization capabilities of alpha-helix-based peptide amphiphiles. *Biomaterials* (2015) 52:517–30. doi: 10.1016/j.biomaterials.2015.02.063

52. Zhang LL, Wei XB, Zhang RJ, Petitte J, Si DY, Li ZX, et al. Design and Development of a Novel Peptide for Treating Intestinal Inflammation. *Front Immunol* (2019) 10:1841. doi: 10.3389/fimmu.2019.01841

53. Zhang LL, Wei XB, Zhang RJ, Si DY, Petitte JN, Ahmad B, et al. A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendothelial Effects. *Int J Mol Sci* (2019) 20(16). doi: 10.3390/ijms20163974

54. Shimamura M, Nakagami H, Shimizu H, Mukai H, Watanabe R, Okuzono T, et al. Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke. *Sci Rep* (2018) 8(1):17770. doi: 10.1038/s41598-018-35898-z

55. da Silva AVR, De Souza BM, Cabrera MPD, Dias NB, Gomes PC, Neto JR, et al. The effects of the C-terminal amidation of mastoparans on their function. *Biomembranes* (2014) 1838(10):2357–68. doi: 10.1016/j.biomem.2014.06.012

56. Geng Y, Xing L, Sun MM, Su FC. Immunomodulatory effects of sulfated polysaccharides of pine pollen on mouse macrophages. *Int J Biol Macromol* (2016) 91:846–55. doi: 10.1016/j.jbiomac.2016.06.021

57. Li XQ, Xu W. TLR4-mediated activation of macrophages by the polysaccharide fraction from Polyergus umbellatus (pers.) Fries. *J Ethnopharmacol* (2011) 135(1):1–6. doi: 10.1016/j.jep.2010.06.028

58. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. *Nat Rev Immunol* (2012) 12(3):168–79. doi: 10.1038/nri3151

59. Roh E, Lee HS, Kwak JA, Hong JT, Nam SY, Jung SH, et al. MD-2 as the Target of Nonlipid Chalcone in the Inhibition of Endotoxin LPS-Induced TLR4 Activity. *J Infect Dis* (2011) 203(7):1012–20. doi: 10.1093/infdis/jiq155

60. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* (2009) 458(7242):1191–U130. doi: 10.1038/nature07830

61. Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. *Biotechnol Adv* (2012) 30(1):251–60. doi: 10.1016/j.biotechadv.2011.05.014

62. Zhang D, Cheng L, Huang X, Shi W, Xiang J, Gan H. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-kappa B activation. *Int J Colorectal Dis* (2009) 24(1):5–12. doi: 10.1007/s00053-008-544-7

63. Hayden MS, Ghosh S. Signaling to NF-kappa B. *Gene Dev* (2004) 18(18):2195–224. doi: 10.1101/gad.1228704

64. Bayraktar O, Tekin N, Aydin O, Akyuz F, Musmum A, Burukoglu D. Effects of S-allyl cysteine on lung and liver tissue in a rat model of lipopolysaccharide-induced sepsis. *N-S Arch Pharmacol* (2015) 388(3):327–35. doi: 10.1007/s00210-014-1076-z

65. Williams R. Global challenges in liver disease. *Hepatology* (2006) 44(3):521–6. doi: 10.1002/hep.21347

66. Buel MG, Berin MC. Neutrophil-Independent of the Initiation of Colonic Injury - Comparison of Results from 3 Models of Experimental Colitis in the Rat. *Digest Dis Sci* (1994) 39(12):2575–88. doi: 10.1007/BF02087693

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Wei, Zhang, Koci, Si, Ahmad, Guo and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction in which does not comply with these terms.